Product Pipeline

Pipeline Overview

Product Mechanism Ownership Indication Preclinical Clinical Proof-of-Concept Pivotal
CG-806 BTK (wildtype and mutant) Aptose: WW
Crystal Genomics: Korea
CLL & NHL
complete
CLL & NHL Preclinical Phase complete
in progress
Clinical Proof-of-Concept Phase in progress
not started
Pivotal Phase not started
CG-806 FLT3 (wildtype and mutant) Aptose: WW
Crystal Genomics: Korea
AML
complete
AML Preclinical Phase complete
in progress
Clinical Proof-of-Concept Phase in progress
not started
Pivotal Phase not started
APTO-253 MYC Aptose: WW AML & MDS
complete
AML & MDS Preclinical Phase complete
in progress
Clinical Proof-of-Concept Phase in progress
not started
Pivotal Phase not started
APL-581 BRD4/JAK Aptose and Ohm Hematologic Cancers
in progress
Hematologic Cancers Preclinical Phase in progress
not started
Clinical Proof-of-Concept Phase not started
not started
Pivotal Phase not started
CG-806 for B-cell Tumors

CG-806 for B-cell Tumors

Oral, Mutation-Agnostic FLT3/BTK Inhibitor

CG-806 is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.

View Candidate
CG-806 for Myeloid Tumors

CG-806 for Myeloid Tumors

Oral, Mutation-Agnostic FLT3/BTK Inhibitor

CG-806 is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies.

View Candidate
APTO-253 for Myeloid Tumors

APTO-253 for Myeloid Tumors

First-in-class MYC Inhibitor

APTO-253 is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

View Candidate
Posters & Presentations

Posters & Presentations

Our online library includes numerous publications, including presentations, posters, and other media that provide additional information on preclinical and clinical studies of our drug candidates.

View Posters & Presentations